{"entity":{"id":"shanghai-pharmaceuticals","kind":"company","name":"Shanghai Pharmaceuticals","aka":["Shanghai Pharmaceuticals Holding","SPH","上海医药","HKEX:2607","SSE:601607"],"tldr":"Shanghai Pharmaceuticals is one of China's largest drug makers and distributors; its research arm is developing SPH4336, an oral CDK4/6 inhibitor for breast cancer.","summary":"Shanghai Pharmaceuticals Holding, listed in Shanghai and Hong Kong, manufactures generic and innovative medicines and runs one of China's biggest pharmaceutical distribution networks. Its oncology research includes SPH4336, a selective CDK4/6 inhibitor in phase 1/2 trials with endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer, and the PD-L1 and TIGIT programmes of its biologics subsidiaries.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.sphchina.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["sph4336"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"pharma","website":"https://www.sphchina.com/","ticker":"HKEX:2607","stage":"public","investors":[],"funding":[]},"route":"/companies/shanghai-pharmaceuticals/","neighbours":{"drug":[{"id":"sph4336","kind":"drug","name":"SPH4336","route":"/drugs/sph4336/"}]}}